Scientists from the Institute of Molecular Genetics of the Czech Academy of Sciences, in collaboration with the Faculty of ...

Researchers at Kumamoto University have uncovered a previously unknown molecular mechanism by which human T-cell leukemia ...

Orum Therapeutics (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief ...

Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) ...

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with ...

A research team has developed an AI-based personalized cancer vaccine design technology that enables long-term immunity that ...

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies ...

Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

Lymphatic malformations (LMs) are congenital vascular anomalies characterized by abnormal lymphatic development, leading to ...

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Medscape Medical News talked with researcher Stacie Dusetzina about the prospects for a single-payer program to help with the ...